Trial Profile

A Multicenter Phase I/Ib Study of Capmatinib Plus Trametinib in Patients With Metastatic MET Exon 14 Skipping Mutation Positive NSCLC

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 13 Jun 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Capmatinib (Primary) ; Trametinib (Primary)
Indications Non-small cell lung cancer
Focus Adverse reactions

Most Recent Events

07 Jun 2024 Status changed from recruiting to discontinued.
15 Aug 2022 Status changed from not yet recruiting to recruiting.
10 Aug 2022 Planned initiation date changed from 18 Jul 2022 to 30 Aug 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com